このエントリーをはてなブックマークに追加
ID 54508
JaLCDOI
FullText URL
Thumnail 70_4_299.pdf 1.82 MB
Author
Wada, Koichiro Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Uehara, Shinya Department of Urology, Kawasaki Hospital, Kawasaki Medical School
Ishii, Ayano Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sadahira, Takuya Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamamoto, Masumi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Mitsuhata, Ritsuko Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takamoto , Atsushi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Araki, Motoo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kobayashi, Yasuyuki Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Masami Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Toyohiko Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hotta, Katsuyuki Center for innovative Clinical Medicine, Okayama University Hospital
Nasu, Yasutomo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Abstract
Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.
Keywords
probiotics
lactobacilli
Lactobacillus crispatus
urinary tract infection
vaginal suppository
Amo Type
Clinical Study Protocols
Published Date
2016-08
Publication Title
Acta Medica Okayama
Volume
volume70
Issue
issue4
Publisher
Okayama University Medical School
Start Page
299
End Page
302
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2016 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
Web of Sience KeyUT